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Introduction
Stereotactic body radiation therapy (SBRT) combines 
conformal radiation dose-shaping,  tumor motion 
management, and on-board daily imaging to deliver high 
doses of radiation in five or fewer treatments (1,2). These 
technological advances in radiation delivery over the last 
decade have allowed safer and more effective dose escalation 
to patients with non-small cell lung cancer (NSCLC). For 
early-stage, medically non-operable NSCLC, SBRT has 
become the standard of care (3). RTOG 0236 established 
SBRT could achieve an impressive 5-year tumor control 
rate of 93% (4,5), with minimal pulmonary toxicity (6). 
However, systemic progression remains problematic. 
Regional and distant failure rates occur in at least 30% 
of patients, with even higher rates with increasing tumor 
size (5,7-11). Medically inoperable patients often cannot 
safely receive adjuvant chemotherapy to help with distant 
control. Immunotherapy, which is better tolerated than 
chemotherapy (12), has recently been heralded as the 
“fourth pillar” of oncologic treatment (13). Food and Drug 
Administration (FDA)-approved antibody drugs currently 
target cytotoxic T-lymphocyte protein 4 (CTLA-4), 
programmed cell-death protein 1 (PD-1), and programmed 
death-ligand 1 (PD-L1). Activation of CTLA-4 and PD-1 
receptors on T cells downregulates the adaptive immune 
response. This prevents auto-immunity, but checkpoint 
inhibition can also be hijacked by tumors seeking to avoid 
immune surveillance (14). By targeting these checkpoint 
inhibitors, immunotherapy has the potential to take the 
brakes off one’s own immune system to seek out and destroy 
cancer cells. 
Immunotherapy has had mixed success in the locally 
advanced and metastatic NSCLC setting. Nivolumab, a 
PD-1 inhibitor, was compared in a phase 3 trial to platinum-
based chemotherapy for metastatic or recurrent NSCLC 
with PD-L1 expression ≥5% (15). There was no difference 
in progression-free survival (PFS) or overall survival 
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(OS), but patients tolerated nivolumab better (grades 
3–4 adverse event 18% vs. 51%). Similarly, ipilimumab, a 
CTLA-4 inhibitor, did not improve PFS or OS when added 
to carboplatin/paclitaxel in metastatic NSCLC (16). In 
contrast, KEYNOTE 24 tested pembrolizumab, a PD-1 
inhibitor, compared to platinum-based chemotherapy in 
metastatic NSCLC patients with tumor PD-L1 expression 
≥50%, and both PFS and OS were significantly improved 
with a 45% response rate (17). The PACIFIC trial tested 
adjuvant durvalumab, a PD-L1 inhibitor, against placebo 
after definitive chemoradiation for stage III NSCLC (18). 
Durvalumab significantly improved median PFS from 5.6 
to 16.8 months. The PFS benefit was seen even when the 
tumor had PD-L1 expression <25%. Atezolizumab, also a 
PD-L1 inhibitor, improved OS compared to docetaxel in 
metastatic NSCLC regardless of PD-L1 expression (19). 
The overall success of checkpoint inhibitors is tempered by 
the variable response rate, which may be improved upon 
when combined with radiation therapy. Several excellent 
reviews on this subject have been recently published and we 
refer you to them for additional references (20-24). In this 
fast-changing field of immuno-radiation therapy, we will 
highlight updates from ongoing clinical trials and offer our 
perspective for future trials.
Rationale for combining SBRT with 
immunotherapy
SBRT tumor debulking may improve immunotherapy 
response. A recent publication in 29 patients with stage 
IV melanoma treated with pembrolizumab found 74% of 
patients had an immunologic response seen in peripheral 
blood draws, but only 38% achieved a radiographic clinical 
response (25). Using Ki-67 as a marker of proliferation 
of PD-1+ T cells, the authors measured the Ki-67 
percentage cell staining to tumor burden (sum of the long-
axis of all measurable lesions) ratio after patients received 
pembrolizumab. A ratio >1.9 was associated with improved 
response and OS. One rationale for tumor debulking lies 
in T cell exhaustion, a phenomenon whereby inhibitory 
signals from the tumor overwhelm T cell activation (26). 
In patients with limited or oligometastatic disease, SBRT 
could reduce the tumor burden and allow re-invigorated T 
cells to find and destroy micrometastatic disease.
Radia t ion  has  a l so  been  shown to  upregula te 
immunogenic cell surface markers. MHC class I is a 
molecule that presents intracellular antigens to the 
cell surface for T cells to recognize foreign peptides. 
Their expression is down-regulated in tumors to evade 
immune recognition (20). Reits et al. were able to show 
that radiation increases MHC class I expression in a dose 
dependent manner, and mice exposed to both radiation and 
immunotherapy had a prolonged tumor response compared 
to mice receiving either therapy alone (27). Calreticulin 
and HMGB1 are other antigen-presenting proteins that 
have been found to be upregulated by radiation (28). Thus, 
radiation may synergize with immunotherapy by helping 
unmask tumor antigens.
Radiation can also engage the innate immune system. 
FAS is a death receptor that catalyzes the apoptotic cascade 
when it encounters FAS ligand, found on activated T cells. 
Chakraborty et al. found that one 8 Gy dose of radiation 
upregulated FAS on tumor cells in situ for up to 11 days and 
increased T cell infiltration and killing (29). Natural killer 
cells can also be alerted to kill tumor cells by radiation-
induced NKG2D expression (30). There is thus a halo 
effect, where tumor cells primed to be recognized by 
undergoing apoptosis after radiation are engulfed in an 
overwhelming immune response from neighboring activated 
immune cells.
Radiation, unfortunately, is a double-edged sword. 
Prolonged fractionated radiation courses to large vascular 
volumes have been shown to deplete circulating lymphocytes 
in all body sites, sometimes up to a year after radiation 
(31-34). Lymphocytes are among the most radiosensitive 
cells in the body, with in vitro data showing 50% cell 
killing after 2 Gy and 10% cell killing after 0.5 Gy (35). 
In locally advanced lung cancer, both cumulative lung and 
heart dose were associated with worsening lymphopenia 
and poor survival (34,36). Hypofractionation or SBRT 
could potentially reduce this iatrogenic immunosuppression 
by limiting the blood pool volume exposed to daily low-
intermediate dose radiation (37,38). Furthermore, radiation 
up-regulates cell surface PD-L1 expression (39), which 
by itself can limit the immunogenic cell death desired 
for optimal local control. However, Deng et al. has 
shown blockade of PD-L1 after irradiation diminishes 
the infiltration of tumor suppressor cells (39), further 
rationalizing the combination of hypofractionated radiation 
with checkpoint inhibitors.
The abscopal effect is a much-discussed hope of many 
radiation oncologists. Simply put, can we radiate a tumor 
and create anti-tumor effects outside of the irradiated field? 
The mechanism of the abscopal effect is hypothesized to 
be immune-mediated. Tumor-specific antigens revealed 
by irradiation need to be recognized and picked up by 
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dendritic cells, which then activate T cells at neighboring 
lymph nodes (40). Efforts to understand and exploit the 
abscopal effect have ramped up since checkpoint inhibitors 
were found to have increased immunomodulatory activity 
compared to activating cytokines (e.g., IL-2) and infusions 
of activated immune cells. However, it is still unclear 
what the optimal radiation dose, fractionation schedule, 
and timing with immunotherapy is to induce an abscopal 
effect. Most pre-clinical studies have used single dose or 
hypofractionated courses with large (≥6 Gy) doses per 
fraction (40). In order to better study this, clinically relevant 
models of cancer development beyond orthotopic tumor 
models need to be developed. 
Clinical data combining radiation with 
immunotherapy 
The introduction of immunotherapy for metastatic cancer 
treatment has corresponded with increasing clinical case 
reports of the abscopal effect. Reynders et al. compiled data 
from 23 case reports, in an effort to generate momentum 
in studying this phenomenon (41). Radiation dose and 
fractionation varied, ranging from 14.4 Gy in 12 fractions 
to 18–26 Gy in a single fraction. Time to documented 
abscopal response ranged between less than 1 and 24 
months, with a median reported time of 5 months. Once 
an abscopal response was achieved, a median time of 13 
months went by before disease progression occurred or the 
reported follow-up ended (range, 3–39 months). Of four 
reported cases of abscopal effect in a patient with a primary 
lung tumor, two were in combination with immunotherapy. 
The combination of immunotherapy and radiation 
therapy has been studied more systematically in the 
metastatic setting as well. A secondary analysis of 98 
metastatic NSCLC patients treated on the phase 1 
KEYNOTE-001 pembrolizumab trial from the University 
of California, Los Angeles found that PFS [hazard ratio 
(HR) =0.56, 95% confidence interval (CI), 0.34–0.91] and 
OS (HR =0.58, 95% CI, 0.36–0.94) were improved in 
patients that had received any prior radiation (43%) (42). 
There was no difference in positive PD-L1 status in 
patients receiving prior radiation vs. not (71% vs. 80%, 
respectively, P=0.75). Of the patients receiving prior 
radiation, 91% was to extracranial sites; 74% was delivered 
with palliative intent; SBRT was used in 29% of cases. 
However, the group with prior radiation had been exposed 
to more lines of systemic therapy (P=0.02) and time from 
diagnosis to starting pembrolizumab was longer (26 vs. 17 
months, P=0.04).
Similarly, a retrospective analysis of 164 metastatic 
NSCLC patients treated with PD-1/PD-L1 inhibitors from 
Massachusetts General Hospital compared outcomes in 
patients receiving thoracic radiation (n=73) or not (n=91) (43). 
Most patients were treated with a definitive radiation dose 
(median 60 Gy, range, 44–79.1 Gy), and the median time 
to checkpoint inhibitor initiation after radiation was 8.6 
months. In multivariable analysis, the thoracic radiation 
group trended to improved OS (HR =0.66, 95% CI, 0.42–
1.01) despite including fewer favorable adenocarcinoma 
patients (49% vs. 75%, P=0.001) with targetable mutation 
(4% vs. 16%, P=0.01). Thus, the two prior studies suggest 
there may be clinical synergy between checkpoint inhibitors 
and radiation therapy. 
In an interesting retrospective study from China, 
outcomes of  pat ients  with a  var iety  of  advanced 
malignancies receiving SBRT combined with adoptive 
immunotherapy were better than outcomes of patients 
receiving SBRT alone (44). In the study, re-injection of the 
patient’s own interferon-activated monocytes combined with 
SBRT improved the total response rate (RECIST partial 
or complete response) compared to SBRT alone (66.8% 
vs. 60.2%, P<0.05). A median total dose of 43 Gy (range, 
18–65 Gy) given in 4–18 Gy per fraction was prescribed. 
However, this was a heterogeneous group of patients and 
tumor response outside of the irradiated field was not 
specified, which limits interpretation and generalization for 
this review.
The first phase I–II prospective trial combining SBRT 
with immunotherapy was updated last year. Tang et al. 
from MD Anderson Cancer Center designed a trial testing 
concurrent vs. sequential ipilimumab (4 cycles every 3 
weeks, 3 mg/kg) and SBRT (50 Gy in 4 fractions or 60 Gy 
in 10 fractions) targeted to liver or lung metastases. In the 
phase I portion, 7/31 (23%) had clinical benefit, either a 
partial response (3 patients) or stable disease lasting more 
than 6 months (4 patients) outside the irradiated field, 
but 34% of patients experienced grade 3 toxicity (most 
commonly colitis, liver toxicity, and a maculopapular 
rash). Liver SBRT produced greater T cell activation, 
which was associated with clinical benefit (45). In the 
phase 2 update at the 2017 American Society for Radiation 
Oncology (ASTRO) annual conference, 100 patients had 
been enrolled. Clinical benefit, defined as stable disease 
or response, was seen in 67% of patients with NSCLC. 
Stable disease was seen in 60% of the sequential 60 Gy 
group, 50% of the sequential 50 Gy lung group, 45% of the 
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concurrent 50 Gy lung group, 35% of the concurrent 50 Gy 
liver group, and 30% of the sequential 50 Gy liver group. 
In contrast to the phase I results, patients who received 
sequential radiation to lung metastases rather than to liver 
metastases had better PFS (P=0.055, 95% CI, 3.7–6.4) and 
OS (P=0.059, CI, 7.9–20.0). No differences were found 
between the concurrent lung or liver groups for PFS (P=0.2) 
or OS (P=0.3) (46).
Most recently, the University of Chicago published a 
phase I study of multisite SBRT followed by pembrolizumab 
in metastatic solid tumor patients (47). Two to four 
metastases (94.5% were two metastases) were targeted with 
SBRT to 30–50 Gy in 3–5 fractions, and pembrolizumab 
200 mg every 3 weeks was initiated 7 days after completion 
of SBRT. The cohort of 73 patients was heavily pre-treated, 
with a median of five prior therapies. Out of 151 metastases 
irradiated, 68 were in the lung, 24 in the liver, 28 in other 
abdomen/pelvis sites, 16 in the bone, and 15 near the spine. 
The abscopal response rate (RECIST, 30% reduction) 
using the aggregate diameter of all nonirradiated target 
metastases was 13.5%; however, the response rate in any 
single nonirradiated target metastasis was an impressive 
26.9%. Median PFS was 3.1 months, but it was not reported 
if patients with an initial response had a sustained response. 
Grade 3 toxicity was seen in 6 patients (pneumonitis n=3; 
colitis n=2; hepatic toxicity n=1). These promising results in 
a heterogenous group of tumors with agnostic PD-L1 status 
support further studies combining checkpoint inhibitors 
with SBRT. 
Finally, short-term safety of combining thoracic 
SBRT and immunotherapy was recently explored in 
a combined analysis of two prospective trials ongoing 
at MD Anderson (48). The first was the phase 1–2 trial 
testing SBRT with ipilimumab detailed above. The second 
was another ongoing phase 1–2 trial testing SBRT with 
concurrent pembrolizumab in metastatic NSCLC. SBRT 
dose was 50 Gy in 4 fractions or 60 Gy in 10 fractions. Out 
of 60 patients with a median follow up of 6.9 months (range, 
0.5–30.9 months), there were no grade ≥4 toxicities. There 
were 34 grade 3 toxicities experienced by 15 patients (9 
grade 3 pulmonary toxicities experienced by 4 patients) with 
no difference between the ipilimumab and pembrolizumab 
groups. These short-term pulmonary toxicity rates were on 
par with RTOG 0236, in which 8 of 55 patients developed 
grade 3 respiratory events (4). Notably, no iatrogenic 
leukopenia was seen with SBRT, suggesting SBRT and 
immunotherapy have non-intersecting and complementary 
toxicity profiles.
Future directions
As more interest is generated in combining radiation 
with immunotherapy, it is important to recognize that 
tumors with a higher mutational burden like NSCLC and 
melanoma appear to be more likely to respond to protocols 
involving immunotherapy (49). Prior trials combining 
ipilimumab with a palliative 8 Gy single dose of radiation 
in metastatic prostate cancer (50,51) were possibly doomed 
by choosing a non-ablative dose in a mutationally quiet 
cancer (52). The optimal dose and fractionation may 
also differ for each cancer type. A recent case series of 
47 metastatic melanoma patients found an abscopal effect 
was most likely to occur when fraction sizes ≤3 Gy were 
utilized (53). Preliminary evidence from the MD Anderson 
phase II trial indicate that treating the largest lesion in 
metastatic NSCLC with 60 Gy in 10 fractions may have the 
most activity when combined with ipilimumab (46). Pre-
clinical data supports using a hypofractionated regimen 
of 3–5 fractions with dose per fraction <10–12 Gy, but 
dose and fractionation will need to be further evaluated 
in clinical trials (54). Response rates and clinical benefit 
of other immune checkpoint inhibitors are also actively 
being investigated (Table 1), and the optimal combination of 
therapy and sequencing with SBRT is still to be determined.
SBRT and immunotherapy protocols are now in 
development for non-metastatic NSCLC patients (Table 2). 
Since decreased tumor burden has been associated with 
increased response to immunotherapy (25), this strategy is 
promising. Results from the PACIFIC trial already showed 
adjuvant immunotherapy after definitive chemoradiation 
in stage III NSCLC improved PFS (18), regardless of 
tumor PD-L1 expression. This suggests that radiation 
may work synergistically with immunotherapy, as prior 
trials in the metastatic setting using immunotherapy alone 
were mostly only positive in tumors with positive PD-L1 
expression. However, the local failure rate of conventionally 
fractionated radiation with concurrent chemotherapy 
approaches 40%, and efforts to dose-escalate conventional 
radiation have been limited by cardiac and pulmonary 
toxicity (55-58). The future may combine the conformal 
ablative power of an SBRT boost to residual PET-avid 
disease (59) to further maximize the efficacy of adjuvant 
immunotherapy.
In early stage NSCLC, the rationale for adding adjuvant 
immunotherapy to SBRT is even greater. Regional and 
distant failure rates of at least 30% (11) demand a tolerable 
systemic solution in this medically frail population. 
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Table 1 Active clinical trials involving SBRT and immunotherapy in metastatic lung cancer 
NCT number Title (study drug if not in title) Recruitment Study endpoint Phase Enrollment
NCT02239900 Ipilimumab and Stereotactic Body Radiation Therapy 
(SBRT) in Advanced Solid Tumors
MD Anderson, Houston, 
TX; recruiting 120
Safety, irRC 
response rate
1–2 Active, closed 
to enrollment
NCT02444741 Pembrolizumab and Stereotactic Body Radiation 
Therapy (SBRT) in Patients With Non-Small Cell Lung 
Cancer (NSCLC)
MD Anderson, Houston, 
TX; recruiting 104
Safety, irRC 
response rate, 
PFS
1–2 Open
NCT02839265 FLT3 Ligand Immunotherapy and Stereotactic 
Radiotherapy for Advanced Non-small Cell Lung 
Cancer (FLT3)
Albert Einstein, NYC, 
NY; recruiting 29
4-month PFS 2 Open
NCT03168464 Radiation and Immune Checkpoints Blockade in 
Metastatic NSCLC (nivolumab/ipilimumab)
Cornell, NYC, NY; 
recruiting 45
Response rate, 
PFS, OS
1–2
NCT03275597 Phase Ib Study of Stereotactic Body Radiotherapy 
(SBRT) in Oligometastatic Non-small Lung Cancer 
(NSCLC) With Dual Immune Checkpoint Inhibition 
(durvalumab/tremelimumab)
University of Wisconsin, 
Madison; recruiting 21
Safety, PFS, OS 1 Open
NCT03223155 Evaluate Concurrent Or Sequential Ipilimumab, 
Nivolumab, and Stereotactic Body Radiotherapy in 
Patients With Stage IV Non-Small Cell Lung Cancer
University of Chicago, 
IL; recruiting 80
Safety, 
response rate
1 Open
NCT03313804 Priming Immunotherapy in Advanced Disease With 
Radiation (any checkpoint inhibitor)
University of Kentucky, 
Lexington; recruiting 57
6-month PFS 2 Open
NCT03035890 Hypofractionated Radiation Therapy to Improve 
Immunotherapy Response in Non-Small Cell Lung 
Cancer (nivolumab, pembrolizumab, or atezolizumab)
West Virginia University; 
recruiting 33
Response rate, 
OS, PFS, QoL
1
NCT02831933 Trial of Stereotactic Body Radiation and Gene 
Therapy Before Nivolumab for Metastatic Non-Small 
Cell Lung Carcinoma (ENSIGN)
Methodist Hospital, 
Houston, TX; recruiting 
29
Response rate, 
PFS, OS
2 Open
NCT03224871 A Pilot Study of Interlesional IL-2 and RT in Patients 
With NSCLC (nivolumab/pembrolizumab)
University of California, 
Davis; recruiting 30
Safety, DFS 1 Open
NCT03158883 Avelumab and Stereotactic Ablative Radiotherapy in 
Non-responding and Progressing NSCLC Patients
University of California, 
Davis; recruiting 26
Response rate, 
PFS, OS, irRC
1 Open
NCT03176173 Radical-Dose Image Guided Radiation Therapy in 
Treating Patients With Metastatic Non-small Cell 
Lung Cancer Undergoing Immunotherapy (nivolumab, 
pembrolizumab, or atezolizumab)
Stanford University, CA; 
recruiting 85
PFS, OS, 
ctDNA changes
2 Open
NCT03050060 Image Guided Hypofractionated Radiation Therapy, 
Nelfinavir Mesylate, Pembrolizumab, Nivolumab and 
Atezolizumab in Treating Patients With Advanced 
Melanoma, Lung, or Kidney Cancer
University of 
Washington, Seattle; 
recruiting 120
Response rate, 
PFS, OS
2 Open
NCT02623595 A Study of SBRT in Combination With rhGM-CSF for 
Stage IV NSCLC Patients Who Failed in Second-line 
Chemotherapy
Wuhan University, 
China; recruiting 60
Abscopal effect 
rate, OS, PFS
2 Open
NCT03509584 Phase I Multicenter Trial Combining Nivolumab, 
Ipilimumab and Hypo-fractionated Radiotherapy for 
Pretreated Advanced Stage Non-small Cell Lung 
Cancer Patients
France; recruiting 24 Safety 1 Not yet open
DFS, disease free survival; irRC, immune related response criteria; PFS, progression free survival; OS, overall survival; QoL, quality of life; 
ctDNA, circulating tumor DNA.
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Table 2 Active clinical trials involving SBRT and immunotherapy in non-metastatic lung cancer
NCT number Title (study drug if not in title) Recruitment Study endpoint Phase Enrollment
NCT03574220 Pembrolizumab After Lung SBRT for Medically Inoperable 
Early Stage Non-small Cell Lung Cancer
Cleveland Clinic, 
Ohio; recruiting 15
Safety, DMFS, 
DFS, OS, LC
1 Not yet 
open
NCT03383302 SBRT With Immunotherapy in Early Stage Non-small 
Cell Lung Cancer: Tolerability and Lung Effects (STILE) 
(nivolumab)
United Kingdom; 
recruiting 31
Lung toxicity, 
DFS, OS, QoL
1–2 Not yet 
open
NCT03446547 Ablative STEreotactic RadiOtherapy wIth Durvalumab 
(durvalumab) (ASTEROID)
Sweden; recruiting 
216
PFS, OS, LC, 
QoL
2 Open
NCT03050554 Stereotactic Body Radiation Therapy (SBRT) Combined 
With Avelumab (Anti-PD-L1) for Management of Early Stage 
Non-Small Cell Lung Cancer (NSCLC)
University of 
California, San 
Diego; recruiting 56
Safety, PFS, 
LRC, OS
1–2 Open
NCT03110978 Clinical Trials Comparing Immunotherapy Plus Stereotactic 
Ablative Radiotherapy (I-SABR) Versus SABR Alone for 
Stage I, Selected Stage IIa or Isolated Lung Parenchymal 
Recurrent Non-Small Cell Lung Cancer: I-SABR (nivolumab)
MD Anderson, 
Houston, TX; 
recruiting 140
EFS, OS, 
toxicity
2 Open
DMFS, distant metastasis free survival; DFS, disease free survival; EFS, event free survival; PFS, progression free survival; OS, overall 
survival; LC, local control; LRC, locoregional control; QoL, quality of life.
We hypothesize that use of adjuvant immunotherapy 
will reduce locoregional and distant recurrence with a 
resultant improvement in OS following SBRT for early 
stage NSCLC. Compared with cytotoxic chemotherapy, 
we expect that this will be readily tolerable in this patient 
population, and lead to minimal impact in quality of life. 
NRG Oncology is developing a phase 3 trial of adjuvant 
durvalumab after SBRT in early stage NSCLC, which 
will test this hypothesis. In the marriage of SBRT with 
immunotherapy, we are still in the honeymoon period. 
Time will tell if these early promises will last.
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